CN117159786A - Preparation method of chitosan hydrogel for regenerating wound healing - Google Patents
Preparation method of chitosan hydrogel for regenerating wound healing Download PDFInfo
- Publication number
- CN117159786A CN117159786A CN202311110166.4A CN202311110166A CN117159786A CN 117159786 A CN117159786 A CN 117159786A CN 202311110166 A CN202311110166 A CN 202311110166A CN 117159786 A CN117159786 A CN 117159786A
- Authority
- CN
- China
- Prior art keywords
- egcg
- amino
- preparation
- solution
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 230000029663 wound healing Effects 0.000 title claims abstract description 26
- 230000001172 regenerating effect Effects 0.000 title claims abstract description 11
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 9
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 48
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 42
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims abstract description 39
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical group OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims abstract description 34
- 238000005576 amination reaction Methods 0.000 claims abstract description 16
- 238000011065 in-situ storage Methods 0.000 claims abstract description 9
- 238000005538 encapsulation Methods 0.000 claims abstract description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 50
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 41
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 20
- 239000008367 deionised water Substances 0.000 claims description 19
- 229910021641 deionized water Inorganic materials 0.000 claims description 19
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 18
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 16
- 230000000844 anti-bacterial effect Effects 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- PCYGLFXKCBFGPC-UHFFFAOYSA-N 3,4-Dihydroxy hydroxymethyl benzene Natural products OCC1=CC=C(O)C(O)=C1 PCYGLFXKCBFGPC-UHFFFAOYSA-N 0.000 claims description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 8
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 8
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 244000269722 Thea sinensis Species 0.000 claims description 6
- 239000004327 boric acid Substances 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 235000009569 green tea Nutrition 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000010410 layer Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000002390 rotary evaporation Methods 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 3
- 125000003172 aldehyde group Chemical group 0.000 claims description 3
- 238000007112 amidation reaction Methods 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 238000006482 condensation reaction Methods 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 239000008240 homogeneous mixture Substances 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 239000013049 sediment Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 20
- 208000027418 Wounds and injury Diseases 0.000 abstract description 20
- 239000000126 substance Substances 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 230000000975 bioactive effect Effects 0.000 abstract description 4
- 238000012377 drug delivery Methods 0.000 abstract description 2
- 238000010348 incorporation Methods 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 238000013268 sustained release Methods 0.000 abstract description 2
- 239000012730 sustained-release form Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001529739 Prunella <angiosperm> Species 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000008113 selfheal Nutrition 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000002768 Kirby-Bauer method Methods 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920000547 conjugated polymer Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a preparation method of chitosan hydrogel for regenerating wound healing, which comprises the steps of alternately containing catechol and phenylboronic acid groups through an amination F127 derivative and covalently bonding with EGCG for wound healing. There are many types of dynamic chemical bonds and the resulting bioactive hydrogels are injectable and adaptable. Injectable hydrogels also allow for in situ encapsulation and efficient delivery of EGCG to a wound site as drug delivery systems. In addition, EGCG participates in the hydrogel network, and due to pH-sensitive dynamic covalent incorporation of EGCG, controlled sustained release of EGCG can be provided, and simultaneously, EGCG plays a long-term therapeutic role.
Description
Technical Field
The invention relates to a preparation method of a nano composite hydrogel scaffold, belongs to the technical field of medical biological materials, and particularly relates to a preparation method of chitosan hydrogel for regenerating wound healing.
Background
Diabetes mellitus is a comprehensive metabolic disease, and the incidence rate of the diabetes mellitus tends to rise year by year. The total number of diabetics in China reaches 1 hundred million and is growing rapidly, and the method is the country with the largest number of diabetics in the world. Among the complications of diabetes, impaired wound healing ability of diabetics is a typical complication of diabetes, and if chronic injury and ulcer occur on the foot, it is possible to cause diabetic foot, and some patients eventually need amputation treatment, bringing a heavy economic burden to the home and society. The wound healing disorder of the diabetic patients seriously affects the daily life of people, and has important clinical significance for effectively preventing and treating the wound healing disorder of the diabetes.
The wound dressing can promote the rapid closing and healing of the wound and is of great importance to wound management. In the existing wound dressing, the vigorously developed hydrogel dressing family stands out due to the unique combination of the hydrogel dressing family, and can provide a physical barrier and maintain a moist microenvironment on a wound bed, so that the wound is protected from external pollution, a relieving effect is provided, and wound healing is promoted. In particular, injectable hydrogels that can be formed in situ under physiological conditions are widely regarded as the most attractive wound dressing, with additional functions including shape adaptation to cover irregularly shaped or deep wounds and in situ drug encapsulation. In addition to rapid coverage of the wound, if the dressing is unable to maintain its integrity during frequent body movements, it may lead to dysfunction and prolonged healing time.
Therefore, an injectable hydrogel with rapid gelling and self-healing capabilities is very attractive for dressings. The introduction of various reversible interactions as cross-linking agents in the construction of hydrogels is considered a reliable method for producing hydrogels with excellent self-healing capabilities. Among them, self-healing gels based on dynamic borate ester bonds are currently becoming potential scaffolds for tissue engineering, electronic skin and flexible sensor applications. These networks are formed by crosslinking cis-diol-rich polymers with boric acid or boric acid derivatives and have transient crosslinking anchors with special kinetics, thus providing hydrogels with remarkable self-healing properties.
Infection by bacterial contamination remains one of the barriers to wound healing, particularly chronic wounds. Chronic inflammation is often difficult to treat due to high microbial load and oxidative stress. A wide range of applications using antibiotics or the addition of bioactive molecules (growth factors, antioxidants and anti-inflammatory agents) in dressings have been devoted to solving infections and promoting healing. However, overuse of synthetic antibiotics leads to drug resistance, constitutes a great threat to human health, and creates a socioeconomic burden. Hydrogels do not possess antibiotic properties, but are effective in alleviating bacterial infections, and have attracted extensive research interest in wound therapy. As a bio-sustainable enhancer, a natural polyphenol extracted from green tea, such as epigallocatechin-3-gallate (EGCG), a well-known wound healing agent, has been encapsulated into hydrogels to tailor the performance of multifunctional wound dressings.
In addition to an impressive therapeutic effect, EGCG having reactive catechol groups can form EGCG conjugated polymer networks by forming reversible covalent bonds involving borate complexation chemistry as a bonding motif. Interestingly, catechol groups with cellular affinity facilitate contact of bacterial cells with the hydrogel surface, resulting in exposure of the bacterial cells to the inherently antimicrobial components.
Therefore, the introduction of catechol groups into hydrogels is of interest as an effective method for achieving contact enhanced bactericidal activity. In addition, reversible borate linkages tend to react to the pH and competing hydroxylated compounds present in the medium (e.g., glucose), thereby enabling the biomolecules incorporated into the hydrogels to stimulate responsive release.
Thus, it can be inferred that the integration of polyphenols and/or catechol group-containing polymers as functional building blocks is a viable option for achieving both antibacterial and antioxidant functions of wound dressing based on dynamically crosslinked hydrogels with injectability, self-healing, drug release control and biocompatibility.
The hydrogel dressing has great application value and prospect as a new research for curing chronic wound healing. Compared with the hydrogel dressing which directly acts on the wound, the traditional hydrogel dressing has the problems of limitation, incapacity of healing, poor shape matching, weak wound retention capacity, easiness in wound infection and the like.
Disclosure of Invention
The invention aims to provide a preparation method of chitosan hydrogel for regenerating wound healing, which constructs the used thermosensitive hydrogel through reversible covalent crosslinking among amino F127 derivatives, wherein the F127 derivatives alternately contain catechol and phenylboronic acid groups and are covalently bonded with EGCG for wound healing.
Due to the presence of multiple types of dynamic chemical bonds, the resulting bioactive hydrogels are injectable and adaptable, including covalent borate ester bonds and non-covalent hydrogen bonds. More importantly, the therapeutically active dynamic covalent hydrogels conjugated with EGCG exhibit enhanced antibacterial and antioxidant properties.
The invention relates to a preparation method of chitosan hydrogel for regenerating wound healing, which comprises the following process steps of alternately containing catechol and phenylboronic acid groups through amination F127 derivatives and covalently bonding with EGCG for wound healing:
step 1): preparation of amino F127
First, F127 was sulfonylated with p-toluenesulfonyl chloride to give F127-p-toluenesulfonate. Then F127-p-toluenesulfonate reacts with ammonia water to obtain aminated F127;
step 2): preparation of catechol functionalized amino F127
Firstly, utilizing condensation reaction of amino and aldehyde group to make amination F127 react with 3, 4-dihydroxybenzaldehyde so as to obtain catechol functionalized amino F127;
step 3): preparation of phenyl boronic acid functionalized amino F127
The amidation reaction of amino and carboxyl is utilized, and under the action of a catalyst, amination F127 reacts with phenylboronic acid to obtain phenylboronic acid functionalized amino F127;
the reaction time of the amination F127 and the phenylboronic acid is 12-36 h; preferably 24 hours;
step 4): preparation of hydrogels
By utilizing a dynamic covalent bond formed between boric acid and catechol groups in amination F127 and combining in-situ encapsulation of green tea derivative epigallocatechin-3-gallate (EGCG), the injectable self-healing hydrogel with antibacterial activity is prepared.
The method specifically comprises the following process steps:
step 1): preparation of amino F127
F127 was weighed into a 150mL dry two-necked flask and dried under vacuum overnight. The anhydrous dichloromethane and pyridine added first dissolve F127, and the system is a clear and transparent solution. The tosyl chloride is weighed, dissolved by anhydrous dichloromethane, and added into the system drop by a constant pressure dropping funnel under the condition of low-temperature ice bath, and the reaction is carried out at room temperature. After the reaction was completed, methylene chloride was added to the system. Washing with 10mL of 1mol/L hydrochloric acid, emulsifying, standing, layering, and removing the lower layer. Then washed with 10mL of saturated sodium bicarbonate solution and finally with 10mL of water. Rotary steaming, removing dichloromethane, vacuum drying for one night, obtaining F127-p-toluene sulfonate.
F127-p-toluenesulfonate is weighed and dissolved in strong ammonia water (not well dissolved and relatively viscous) and reacted at high temperature by a high-temperature high-pressure reaction kettle. After the reaction, F127-p-toluenesulfonate is found to sink on the lower layer, supernatant and precipitate are treated separately, the supernatant and the precipitate are extracted by dichloromethane with the same volume, then the mixture is stirred by sodium hydroxide with the same volume of 1mol/L, finally water is washed to be neutral, and solvent is removed by rotary evaporation, so that aminated F127 is obtained.
Step 2): preparation of catechol functionalized amino F127
First, F127 was dissolved in deionized water, and NaHCO3 was added to adjust the pH. Then 3, 4-dihydroxybenzaldehyde is added into F127 solution, the temperature is reduced to 25 ℃ by heating and stirring, naBH4 is gradually added at room temperature, and the mixture is vigorously stirred, so that brown suspension is obtained. The sediment was rinsed with water and dissolved in water at an acidic pH. The resulting conjugate was then dialyzed against deionized water in a dialysis tube having an MWCO of 14000D for 3 days. The F127-CA conjugate obtained was freeze-dried and stored at 2-8deg.C.
Step 3): preparation of phenyl boronic acid functionalized amino F127
The amino F127 was dissolved in deionized water, PBA was added to the amino F127 solution in the presence of EDC. HCl and HOBt, and stirred overnight at room temperature at a pH of about 5. The resulting mixture was then precipitated and washed 3 times with isopropanol.
Subsequently, the precipitate was dissolved in deionized water and dialyzed against deionized water in a dialysis tube (MWCO 8000 d) for 3 days. The PBA-bound amino F127 conjugate was then lyophilized and stored at 2-8 ℃ until use.
Step 4): preparation of hydrogels
The sorbitol solution containing EGCG was added to the F127-CA solution and stirred. Then, the F127-PBA solution was added to the homogeneous mixture, and the resulting mixture immediately became a gel.
In the step (1) of the process,
f127 is 3-10 g; preferably 6.9g;
the p-toluenesulfonyl chloride is 0.5 g-2 g; preferably 1.33g;
the room temperature reaction time is 12-48 hours; preferably 24 hours;
the volume of the dichloromethane is 10 mL-40 mL; preferably 30mL;
the amount of F127-p-toluenesulfonate is 1 g-3 g; preferably 2g;
the volume of the concentrated ammonia water is 20-80 mL; preferably 50mL;
the high-temperature reaction temperature is 120-160 ℃; preferably 140 ℃;
the high-temperature reaction time is 4-8 hours; preferably 6h;
the stirring time is 1-3 h; preferably 2 hours.
In the step 2) of the process, the process is carried out,
2-8 g of amino F127; preferably 5g;
the volume of the deionized water is 300-500 mL; preferably 400mL;
6-16 g of 3, 4-dihydroxybenzaldehyde; preferably 11g;
the heating temperature is 40-80 ℃; preferably 60 ℃.
The stirring time is 1-5 h; preferably 3 hours;
3-9 g of sodium borohydride; preferably 6g;
the violent stirring time is 1-5 h; preferably 3 hours.
In the step 3) of the method,
2-8 g of amino F127; preferably 5g;
the volume of the deionized water is 300-700 mL; preferably 500mL;
3-9 g of EDC and HCl; preferably 6.3g;
the HOBt is 3-8 g; preferably 5g;
the PBA is 1-10 g; preferably 5.4g.
The invention provides a preparation method of chitosan hydrogel for regenerating wound healing.
The hydrogel material has injectable, temperature sensitive, EGCG delivery, bioactivity and chronic wound healing. The hydrogel material has good antibacterial and antioxidant functions in the aspects of preventing bacterial infection and scavenging free radicals, and overcomes some problems of the existing hydrogel material for treating chronic wound healing.
The hydrogel material of the invention belongs to the combination of various substances, maintains the advantages of the original substances, and solves the defect of single original material performance. The preparation process of the invention has simple operation, the required raw materials are easy to obtain, and the invention is expected to be widely applied in the field of biomedical engineering materials.
By means of the technical scheme, the preparation method of the hydrogel material has the following beneficial effects:
firstly, the invention utilizes dynamic covalent bond formed between boric acid and catechol group in amination F127 and combines in-situ encapsulation of green tea derivative epigallocatechin-3-gallate (EGCG) to prepare the injectable self-healing hydrogel with antibacterial activity.
The prepared natural injectable hydrogel has good antibacterial and antioxidant functions in the aspects of preventing bacterial infection and scavenging free radicals by utilizing the therapeutic action of catechol groups and EGCG.
EGCG loaded hydrogels also exhibit good biocompatibility, as well as contact antibacterial activity through a "capture and kill" strategy. Dynamic covalent bonding shear thins the gel through the syringe and then self-heals rapidly. The hydrogel of the invention has obvious regenerative wound healing performance, and shows great potential as a novel wound treatment dressing.
Drawings
FIG. 1 shows a scanning electron microscope image of a hydrogel;
FIG. 2 shows cytotoxicity of F127-PC and F127-PC/EGCG;
FIG. 3 shows the release profile of EGCG under various conditions;
FIG. 4 shows the bacteriostatic efficacy of F127-PC/EGCG against E.coli and Staphylococcus aureus.
Detailed Description
The present invention will be described in further detail below by reference to the drawings and effect test examples, which are given for the purpose of illustration only and are not limiting the invention.
The invention relates to a method for wound healing by covalent bonding of an aminated F127 derivative alternately containing catechol and phenylboronic acid groups and EGCG. The resulting bioactive hydrogels are injectable and adaptable due to the presence of multiple types of dynamic chemical bonds; injectable hydrogels also allow for in situ encapsulation and efficient delivery of EGCG to a wound site as drug delivery systems.
In addition, EGCG participates in the hydrogel network, and due to pH-sensitive dynamic covalent incorporation of EGCG, controlled sustained release of EGCG can be provided, and simultaneously, EGCG plays a long-term therapeutic role.
The invention prepares the injectable self-healing hydrogel with antibacterial activity by combining dynamic covalent bonds formed between boric acid and catechol groups in amination F127 and in-situ encapsulation of green tea derivative epigallocatechin-3-gallate (EGCG).
The prepared natural injectable hydrogel has good antibacterial and antioxidant functions in the aspects of preventing bacterial infection and scavenging free radicals by utilizing the therapeutic action of catechol groups and EGCG. Dynamic covalent bonding shear thins the gel through the syringe and then self-heals rapidly.
In addition, in vivo wound healing evaluation in a full-thickness skin defect model shows that hydrogel has obvious regenerative wound healing performance, and shows great potential as a novel wound treatment dressing.
The invention provides a preparation method of chitosan hydrogel for regenerating wound healing, which comprises the steps of alternately containing catechol and phenylboronic acid groups through an amination F127 derivative and covalently bonding with EGCG for wound healing;
the method specifically comprises the following process steps:
step 1): preparation of amino F127
First, F127 was sulfonylated with p-toluenesulfonyl chloride to give F127-p-toluenesulfonate. Then F127-p-toluenesulfonate reacts with ammonia water to obtain aminated F127;
step 2): preparation of catechol functionalized amino F127
Firstly, utilizing condensation reaction of amino and aldehyde group to make amination F127 react with 3, 4-dihydroxybenzaldehyde so as to obtain catechol functionalized amino F127;
step 3): preparation of phenyl boronic acid functionalized amino F127
The amidation reaction of amino and carboxyl is utilized, and under the action of a catalyst, amination F127 reacts with phenylboronic acid to obtain phenylboronic acid functionalized amino F127;
step 4): preparation of hydrogels
By utilizing a dynamic covalent bond formed between boric acid and catechol groups in amination F127 and combining in-situ encapsulation of green tea derivative epigallocatechin-3-gallate (EGCG), the injectable self-healing hydrogel with antibacterial activity is prepared.
The present invention will be described in further detail with reference to specific preferred examples in conjunction with effect test examples, but the present invention is not limited to the following examples.
Example 1: preparation of amino F127
6.9g F127 was weighed into a 150mL dry two-necked flask and dried under vacuum overnight. First, 12.5mL of anhydrous dichloromethane and 12.5mL of pyridine were added to dissolve F127, and the system was a clear and transparent solution. 1.33g of p-toluenesulfonyl chloride was weighed, dissolved in 12.5mL of anhydrous dichloromethane, and the system was added dropwise under low-temperature ice bath conditions using a constant pressure dropping funnel. (after a few drops were added dropwise, the system became a golden clear solution) and reacted at room temperature for 24 hours.
After the completion of the reaction, 30mL of methylene chloride was added to the system. Washing with 10mL of 1mol/L hydrochloric acid, emulsifying, standing, layering, and removing the lower layer. Then washed with 10mL of saturated sodium bicarbonate solution and finally with 10mL of water. The dichloromethane was removed by rotary evaporation and dried in vacuo overnight. 5.4g of F127-p-toluenesulfonate were obtained. 2g of F127-p-toluenesulfonate was weighed, dissolved in 50mL of concentrated aqueous ammonia (not well soluble, relatively viscous.) and reacted at 140℃for 6 hours using a high temperature and high pressure autoclave.
After the reaction, F127-p-toluenesulfonate is found to sink on the lower layer, supernatant and precipitate are treated separately, the supernatant and the precipitate are extracted by dichloromethane with the same volume, then the mixture is stirred for 2 hours by sodium hydroxide with the same volume of 1mol/L, finally the mixture is washed to be neutral by water, and the solvent is removed by rotary evaporation.
Example 2: preparation of catechol functionalized amino F127
First, 5g of F127 was dissolved in deionized water (400 mL) and the pH was adjusted to 7.0 by the addition of NaHCO 3. Then 11g of 3, 4-dihydroxybenzaldehyde was added to the F127 solution, stirred at 60℃for 3 hours, the temperature was lowered to 25℃and NaBH4 (6 g) was gradually added at room temperature, and stirred vigorously for 3 hours to give a brown suspension. The sediment was rinsed with water and dissolved in water at a pH of about 4. The resulting product was then dialyzed against deionized water in a dialysis bag (14000D) for 3 days. The F127-CA conjugate obtained was freeze-dried and stored at 2-8deg.C.
Example 3: preparation of phenyl boronic acid functionalized amino F127
Briefly, 5g of amino F127 was dissolved in deionized water (500 mL), 5.4g of PBA was added to the amino F127 solution in the presence of EDC. HCl (6.3 g) and HOBt (5 g), and stirred at room temperature overnight at a pH of about 5. The resulting mixture was then precipitated and washed 3 times with isopropanol. Subsequently, the precipitate was dissolved in deionized water and dialyzed against deionized water in a dialysis tube (MWCO 8000 d) for 3 days. The PBA-bound amino F127 conjugate was then lyophilized and stored at 2-8 ℃ until use.
Example 4: preparation of hydrogels
A sorbitol solution containing 5mg of EGCG was added to the F127-CA solution and stirred. Then, the F127-PBA solution was added to the homogeneous mixture, and the resulting mixture immediately became a gel. Also, in the absence of EGCG, EGCG-free hydrogels were prepared using the same method. Composition of the hydrogel (component concentration F127-PBA 3.5wt%, F127-CA 5.0wt%, sorbitol 50 wt%). EGCG was dissolved in sorbitol solution followed by F127-CA solution. Respectively designated as F127-PC or F127-PC/EGCG.
As shown in fig. 1, the morphology of the hydrogel was observed with a scanning electron microscope. The hydrogel exhibits a porous crosslinked network structure.
The hydrogel products of the examples of the present invention are described in further detail below by way of efficacy test examples.
Test example 1: cytotoxicity of cells
The toxic effects of F127-PC or F127-PC/EGCG on mouse fibroblast L929 were evaluated by the method of detecting cell activity using CCK-8. The specific operation steps are as follows:
first, mouse fibroblast L929 was inoculated into a 96-well plate at a density of 5000 cells/well, and then placed in a carbon dioxide incubator to culture and adhere overnight. Subsequently, the original medium was aspirated and replaced with fresh complete medium extracts containing F127-PC or F127-PC/EGCG, 5 in parallel for each concentration. The cells were then incubated in an incubator for 24h, 48h and 72h, washed once with PBS after incubation and 100. Mu.L of fresh medium (containing 10% CCK-8) was added to each well.
Incubation in incubator for a period of time, and finally detection and recording of absorbance at 450nm wavelength using a microplate reader, cell viability was calculated by the following formula: cell viability (%) = (experimental group absorbance-blank group absorbance)/(negative control group absorbance-blank group absorbance) ×100%.
As shown in FIG. 2, the cell viability was high at different times for either F127-PC or F127-PC/EGCG, and none of them produced any cytotoxicity to mouse fibroblast L929.
Therefore, it is believed that F127-PC or F127-PC/EGCG materials have excellent biocompatibility and can be used as safe gel materials for the study of chronic wound therapy.
Test example 2: EGCG Release
The pH-dependent degradation of hydrogels and the in vitro drug release behavior were studied. 3.0mL of acetic acid buffers (0.1M) of different pH values (5.0 and 7.4) were carefully added to the test tube as a release medium, and the test tube was placed in a constant temperature shaking water bath (Shanghai's signal laboratory apparatus Co., ltd.) at 37℃for in vitro release experiments, with a shaking rate of 60rad/min. At intervals, 1.5mL of release solution was carefully removed from the supernatant to be tested, and fresh 1.5mL of PBS buffer was then added to the tube. The in vitro release profile of EGCG was calculated using UV measurement of the absorbance peak at 275 nm. The results are shown in figure 3, where an initial burst release of EGCG was observed in both physiological and acidic media. And EGCG is released faster at pH 5.0 than at pH 7.4. Thus, the increased release of EGCG in acidic media under physiological conditions predominates throughout the release time window.
Test example 3: antibacterial property
The prepared hydrogels were evaluated for their bacteriostatic activity against E.coli (E.coli) and Staphylococcus aureus (S.aureus) using an agar disc diffusion test and a surface contact test.
Coli and staphylococcus aureus were revived overnight in Luria-Bertani (LB) broth at 37 ℃. All hydrogel samples were sterilized by uv irradiation prior to detection.
As shown in FIG. 4, the F127-PC/EGCG hydrogel can obviously inhibit the growth of escherichia coli and staphylococcus aureus, and has good antibacterial property.
The present invention is not limited to the preferred embodiments, but can be modified, equivalent, and modified in any way without departing from the technical scope of the present invention.
Claims (8)
1. A method for preparing chitosan hydrogel for regenerating wound healing, characterized in that the method comprises alternately containing catechol and phenylboronic acid groups through amination of F127 derivatives and covalent bonding with EGCG for wound healing;
the method specifically comprises the following process steps:
step 1): preparation of amino F127
First, F127 was sulfonylated with p-toluenesulfonyl chloride to give F127-p-toluenesulfonate. Then F127-p-toluenesulfonate reacts with ammonia water to obtain aminated F127;
step 2): preparation of catechol functionalized amino F127
Firstly, utilizing condensation reaction of amino and aldehyde group to make amination F127 react with 3, 4-dihydroxybenzaldehyde so as to obtain catechol functionalized amino F127;
step 3): preparation of phenyl boronic acid functionalized amino F127
The amidation reaction of amino and carboxyl is utilized, and under the action of a catalyst, amination F127 reacts with phenylboronic acid to obtain phenylboronic acid functionalized amino F127;
step 4): preparation of hydrogels
By utilizing a dynamic covalent bond formed between boric acid and catechol groups in amination F127 and combining in-situ encapsulation of green tea derivative epigallocatechin-3-gallate (EGCG), the injectable self-healing hydrogel with antibacterial activity is prepared.
2. The method of manufacturing according to claim 1, wherein: the specific steps of the step 1) are as follows:
f127 was weighed into a 150mL dry two-necked flask and dried under vacuum overnight; firstly, adding anhydrous dichloromethane and pyridine to dissolve F127, wherein the system is a clear and transparent solution; weighing p-toluenesulfonyl chloride, dissolving the p-toluenesulfonyl chloride with anhydrous dichloromethane, dropwise adding the solution into a system by using a constant-pressure dropping funnel under the low-temperature ice bath condition, and reacting at room temperature; after the reaction is finished, adding methylene dichloride into the system; washing with 10mL of 1mol/L hydrochloric acid, emulsifying, standing, layering, and taking out the lower layer; then washed with 10mL of saturated sodium bicarbonate solution and finally with 10mL of water; rotary steaming, removing dichloromethane, and vacuum drying for one night to obtain F127-p-toluenesulfonate;
weighing F127-p-toluenesulfonate, and dissolving in concentrated ammonia water; high-temperature high-pressure reaction in a high-temperature high-pressure reaction kettle; after the reaction, F127-p-toluenesulfonate is found to sink on the lower layer, supernatant and precipitate are treated separately, the supernatant and the precipitate are extracted by dichloromethane with the same volume, then the mixture is stirred by sodium hydroxide with the same volume of 1mol/L, finally water is washed to be neutral, and solvent is removed by rotary evaporation, so that aminated F127 is obtained.
3. The method of manufacturing according to claim 1, wherein: the step 2) comprises the following specific steps:
first, F127 is dissolved in deionized water, naHCO is added 3 Adjusting the pH; then adding 3, 4-dihydroxybenzaldehyde into the F127 solution, heating and stirring, cooling to 25 ℃, gradually adding sodium borohydride at room temperature, and vigorously stirring to obtain brown suspension; the sediment is washed by water and is dissolved in water with acidic pH value;
the resulting conjugate was then dialyzed against deionized water in a dialysis tube having an MWCO of 14000D for 3 days, and the resulting F127-CA conjugate was lyophilized and stored at 2-8deg.C.
4. The method of manufacturing according to claim 1, wherein: the step 3) comprises the following specific steps:
dissolving amino F127 in deionized water, adding phenylboronic acid to the amino F127 solution in the presence of EDC, HCl and HOBt, and stirring at room temperature overnight to a pH of about 5;
the resulting mixture precipitate was then washed 3 times with isopropanol; subsequently, the precipitate was dissolved in deionized water and dialyzed against deionized water in a dialysis tube with MWCO 8000D for 3 days;
the PBA-bonded amino F127 conjugate F127-PBA was then lyophilized and stored at 2-8 ℃ until use.
5. The method of manufacturing according to claim 1, wherein: the specific steps of the step 4) are as follows:
adding the sorbitol solution containing EGCG into the F127-CA solution, and stirring; then, the F127-PBA solution was added to the homogeneous mixture, and the resulting mixture immediately became a gel.
6. The method of manufacturing as claimed in claim 2, wherein: in the step (1) of the above-mentioned process,
f127 is 3-10 g; preferably 6.9g;
the p-toluenesulfonyl chloride is 0.5 g-2 g; preferably 1.33g;
the room temperature reaction time is 12-48 hours; preferably 24 hours;
the volume of the dichloromethane is 10 mL-40 mL; preferably 30mL;
the amount of F127-p-toluenesulfonate is 1 g-3 g; preferably 2g;
the volume of the concentrated ammonia water is 20-80 mL; preferably 50mL;
the high-temperature reaction temperature is 120-160 ℃; preferably 140 ℃;
the high-temperature reaction time is 4-8 hours; preferably 6h;
the stirring time is 1-3 h; preferably 2 hours.
7. A method of preparation as claimed in claim 3, wherein: in the step 2), the amino F127 is 2-8 g; preferably 5g;
the volume of the deionized water is 300-500 mL; preferably 400mL;
6-16 g of 3, 4-dihydroxybenzaldehyde; preferably 11g;
the heating temperature is 40-80 ℃; preferably 60 ℃.
The stirring time is 1-5 h; preferably 3 hours;
3-9 g of sodium borohydride; preferably 6g;
the violent stirring time is 1-5 h; preferably 3 hours.
8. The method of manufacturing according to claim 4, wherein: in the step 3), the amino F127 is 2-8 g; preferably 5g;
the volume of the deionized water is 300-700 mL; preferably 500mL;
3-9 g of EDC and HCl; preferably 6.3g;
the HOBt is 3-8 g; preferably 5g;
1-10 g of phenylboronic acid; preferably 5.4g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311110166.4A CN117159786B (en) | 2023-08-30 | 2023-08-30 | Preparation method of bioactive hydrogel for regenerating wound healing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311110166.4A CN117159786B (en) | 2023-08-30 | 2023-08-30 | Preparation method of bioactive hydrogel for regenerating wound healing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117159786A true CN117159786A (en) | 2023-12-05 |
| CN117159786B CN117159786B (en) | 2024-03-26 |
Family
ID=88932972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311110166.4A Active CN117159786B (en) | 2023-08-30 | 2023-08-30 | Preparation method of bioactive hydrogel for regenerating wound healing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117159786B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118059324A (en) * | 2024-04-18 | 2024-05-24 | 哈尔滨医科大学 | Hydrogel composition, preparation method and application thereof in cardiac surgery |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2727597A1 (en) * | 2012-11-06 | 2014-05-07 | Centre National de la Recherche Scientifique (CNRS) | Glucose responsive hydrogel comprising pba-grafted hyaluronic acid (ha) |
| US20140193360A1 (en) * | 2011-11-21 | 2014-07-10 | Innotherapy Inc. | Hydrogel comprising catechol group-coupled chitosan or polyamine and poloxamer comprising thiol group coupled to end thereof, preparation method thereof, and hemostat using same |
| CN106947094A (en) * | 2017-03-02 | 2017-07-14 | 四川大学 | Sensitive selfreparing hydrogels of a kind of pH and preparation method thereof |
| CN111110853A (en) * | 2019-12-16 | 2020-05-08 | 温州医科大学 | Temperature-sensitive material with biological adhesion, preparation method thereof and application of drug carrier |
| CN113248732A (en) * | 2021-04-29 | 2021-08-13 | 西安交通大学 | Preparation method of injectable self-adaptive natural hydrogel adhesive |
| CN113563632A (en) * | 2021-09-22 | 2021-10-29 | 南京嘉曜生物科技有限公司 | Chitosan derivative and preparation method and application thereof |
| CN114681661A (en) * | 2022-03-28 | 2022-07-01 | 四川大学 | Hemostatic powder and preparation method thereof |
| CN115212345A (en) * | 2022-06-07 | 2022-10-21 | 河南师范大学 | Polyphenol crosslinked natural polysaccharide-based hydrogel dressing and preparation method and application thereof |
| CN116327895A (en) * | 2023-04-10 | 2023-06-27 | 中国人民解放军陆军军医大学 | Multifunctional hydrogel for anti-inflammatory and bone repair promotion, preparation method and application |
| CN116650710A (en) * | 2023-06-21 | 2023-08-29 | 山东大学 | Mussel inspired multifunctional double-network crosslinked hydrogel wound dressing |
-
2023
- 2023-08-30 CN CN202311110166.4A patent/CN117159786B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140193360A1 (en) * | 2011-11-21 | 2014-07-10 | Innotherapy Inc. | Hydrogel comprising catechol group-coupled chitosan or polyamine and poloxamer comprising thiol group coupled to end thereof, preparation method thereof, and hemostat using same |
| EP2727597A1 (en) * | 2012-11-06 | 2014-05-07 | Centre National de la Recherche Scientifique (CNRS) | Glucose responsive hydrogel comprising pba-grafted hyaluronic acid (ha) |
| CN106947094A (en) * | 2017-03-02 | 2017-07-14 | 四川大学 | Sensitive selfreparing hydrogels of a kind of pH and preparation method thereof |
| CN111110853A (en) * | 2019-12-16 | 2020-05-08 | 温州医科大学 | Temperature-sensitive material with biological adhesion, preparation method thereof and application of drug carrier |
| CN113248732A (en) * | 2021-04-29 | 2021-08-13 | 西安交通大学 | Preparation method of injectable self-adaptive natural hydrogel adhesive |
| CN113563632A (en) * | 2021-09-22 | 2021-10-29 | 南京嘉曜生物科技有限公司 | Chitosan derivative and preparation method and application thereof |
| CN114681661A (en) * | 2022-03-28 | 2022-07-01 | 四川大学 | Hemostatic powder and preparation method thereof |
| CN115212345A (en) * | 2022-06-07 | 2022-10-21 | 河南师范大学 | Polyphenol crosslinked natural polysaccharide-based hydrogel dressing and preparation method and application thereof |
| CN116327895A (en) * | 2023-04-10 | 2023-06-27 | 中国人民解放军陆军军医大学 | Multifunctional hydrogel for anti-inflammatory and bone repair promotion, preparation method and application |
| CN116650710A (en) * | 2023-06-21 | 2023-08-29 | 山东大学 | Mussel inspired multifunctional double-network crosslinked hydrogel wound dressing |
Non-Patent Citations (4)
| Title |
|---|
| CAO JUN等: "A cooling-driven self-adaptive and re1 movable hydrogel coupled with combined chemo-photothermal sterilization for promoting infected wound healing", NANOSCALE, vol. 15, no. 26, 29 May 2023 (2023-05-29), pages 11163 - 11178 * |
| XIAN SIJIE等: "Glucose-Responsive Injectable Thermogels via Dynamic-Covalent Cross-Linking of Pluronic Micelles", ACS BIOMATERIALS SCIENCE & ENGINEERING, vol. 8, no. 11, 1 November 2022 (2022-11-01), pages 4873 - 4885 * |
| 潘玉妹;徐坚;陈强;吴石山;: "智能水凝胶在生物载药领域的研究进展", 化工进展, no. 1, 15 June 2016 (2016-06-15), pages 209 - 215 * |
| 魏金光;陈宇飞;杜春贵;刘宏治;: "温敏性水凝胶在抗菌领域应用的研究进展", 高分子通报, no. 12, 15 December 2015 (2015-12-15), pages 41 - 49 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118059324A (en) * | 2024-04-18 | 2024-05-24 | 哈尔滨医科大学 | Hydrogel composition, preparation method and application thereof in cardiac surgery |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117159786B (en) | 2024-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yuan et al. | A physicochemical double cross-linked multifunctional hydrogel for dynamic burn wound healing: shape adaptability, injectable self-healing property and enhanced adhesion | |
| Qu et al. | Degradable conductive injectable hydrogels as novel antibacterial, anti-oxidant wound dressings for wound healing | |
| Mehrabani et al. | Preparation of biocompatible and biodegradable silk fibroin/chitin/silver nanoparticles 3D scaffolds as a bandage for antimicrobial wound dressing | |
| Zhu et al. | Enhanced healing activity of burn wound infection by a dextran-HA hydrogel enriched with sanguinarine | |
| Moura et al. | Recent advances on the development of wound dressings for diabetic foot ulcer treatment—A review | |
| Song et al. | Novel chitosan based metal-organic polyhedrons/enzyme hybrid hydrogel with antibacterial activity to promote wound healing | |
| CN111234267B (en) | Conductive photo-thermal self-healing composite hydrogel dressing and preparation method and application thereof | |
| CN103083713B (en) | A kind of aseptic polymerization wound-surface cover dressing | |
| CN117159786B (en) | Preparation method of bioactive hydrogel for regenerating wound healing | |
| RU2422133C1 (en) | Hydrophylic gel, method of its obtaining (versions), wound covering and based on it bandage means | |
| Han et al. | A multifunctional mussel-inspired hydrogel with antioxidant, electrical conductivity and photothermal activity loaded with mupirocin for burn healing | |
| Yue et al. | Physical dual-network photothermal antibacterial multifunctional hydrogel adhesive for wound healing of drug-resistant bacterial infections synthesized from natural polysaccharides | |
| CN112778772A (en) | Antibacterial composite hydrogel and preparation method and application thereof | |
| CN107349459B (en) | A kind of glucan base hemostatic and antibacterial promoting healing material and preparation method thereof | |
| CN111518288B (en) | Composite hydrogel wound dressing and preparation method thereof | |
| Xiong et al. | Derma-like antibacterial polysaccharide gel dressings for wound care | |
| CN111494709B (en) | Preparation and application of tissue repair promoting hydrogel with anti-tumor and antibacterial functions | |
| CN114146215A (en) | Injectable hydrogel with antibacterial, antioxidant and hemostatic effects and preparation method and application thereof | |
| Nezhad-Mokhtari et al. | Honey-loaded reinforced film based on bacterial Nanocellulose/gelatin/guar gum as an effective antibacterial wound dressing | |
| CN116059156B (en) | Double-layer network hydrogel microneedle and preparation method and application thereof | |
| CN112587717A (en) | Metal cation crosslinked alginate/bacterial cellulose composite hydrogel antibacterial dressing | |
| CN115382008B (en) | Preparation method of injectable hydrogel suitable for diabetic wound repair | |
| CN116769320A (en) | Temperature-responsive jellyfish collagen hydrogel and preparation method and application thereof | |
| CN114479124B (en) | Self-healing hydrogel, preparation method and application thereof | |
| Hua et al. | Tunicate cellulose nanocrystals strengthened injectable stretchable hydrogel as multi-responsive enhanced antibacterial wound dressing for promoting diabetic wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |